P2B001
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for P2B001, covering 2023-03-21 to 2023-04-07. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease [Phase 2, Phase 3]